Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of SAR443820 in adults with ALS
jRCT2031220078Phase 2Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing SAR443820 with Placebo → SAR443820 (2 arms). Primary endpoints: Change from baseline in the ALSFRS-R total score - Part A and Combined assessment of function and survival (CAFS) score - Part B. Started Aug 2022; status: completed.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2031220078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220078.